Ferguson, M., et al. Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial. Hum Vaccin Immunother, 2025 Dec, 21(1):2579335. PMID: 41194599
0
By
In Scientific Papers
Posted

Ferguson, M., et al. Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial. Hum Vaccin Immunother, 2025 Dec, 21(1):2579335. PMID: 41194599

Respiratory syncytial virus (RSV) is a leading cause of respiratory illness across all age groups, particularly affecting infants, older adults, and individuals with chronic health conditions, [...]

READ MORE
 Rayens, E., et al. Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years. Clin Infect Dis, 2025 Dec 24, 81(5):e441-e445. PMID: 40795767
0
By
In Scientific Papers
Posted

Rayens, E., et al. Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years. Clin Infect Dis, 2025 Dec 24, 81(5):e441-e445. PMID: 40795767

Herpes zoster (shingles) and its complication, herpes zoster ophthalmicus (HZO), are associated with an increased risk of cardiovascular events such as heart attacks and strokes, especially in [...]

READ MORE